Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of...

Full description

Bibliographic Details
Main Authors:	Caroline P. Kerr, Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert, Zachary S. Morris
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Pharmaceutics
Subjects:	targeted radionuclide therapy (TRT) anti-tumor immunity external beam radiation therapy (EBRT) tumor microenvironment (TME)
Online Access:	https://www.mdpi.com/1999-4923/15/1/128

Similar Items

Comparison of radiobiological parameters for 90Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro
by: Yaser H. Gholami, et al.
Published: (2018-09-01)

Methodological guide for assessing the carbon footprint of external beam radiotherapy: A single-center study with quantified mitigation strategies
by: David Ali, et al.
Published: (2024-05-01)

Neuroinflammation in Glioblastoma: Progress and Perspectives
by: Xin Li, et al.
Published: (2024-07-01)

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
by: Philip E. Harris, et al.
Published: (2022-10-01)

The application of radionuclide therapy for breast cancer
by: Anna Musket, et al.
Published: (2024-01-01)

Adjuvant treatments for locally advanced differentiated thyroid cancer: a nationwide survey in Japan
by: Terufumi Kawamoto, et al.
Published: (2023-10-01)

Does Timing of Radiation Therapy Impact Wound Healing in Patients Undergoing Metastatic Spine Surgery?
by: Ranbir Ahluwalia, et al.
Published: (2024-05-01)

Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
by: Karen G. de la Cruz-López, et al.
Published: (2019-11-01)

Radionuclides for Targeted Therapy: Physical Properties
by: Caroline Stokke, et al.
Published: (2022-08-01)

The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells
by: Anja Charlotte Lundgren Mortensen, et al.
Published: (2019-09-01)

Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy
by: Ruth Christine Winter, et al.
Published: (2024-08-01)

From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy
by: Zhengzhou Qiu, et al.
Published: (2024-12-01)

Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer
by: Tyrillshall S. T. Damiana, et al.
Published: (2021-05-01)

The role of RNA methylation in tumor immunity and its potential in immunotherapy
by: Yan Li, et al.
Published: (2024-06-01)

Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma
by: Ming-Cheng Guan, et al.
Published: (2022-09-01)

Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression
by: Hussein Sabit, et al.
Published: (2024-10-01)

Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy
by: Ee Wern Tan, et al.
Published: (2022-10-01)

Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model
by: Pierre-Simon Bellaye, et al.
Published: (2024-10-01)

Safety and efficacy of stereotactic ablative brachytherapy as a salvage therapy for recurrent chest wall cancer: A retrospective, multicenter study
by: Bin Huo, et al.
Published: (2023-02-01)

Nonsurgical Treatment for Localised Hepatocellular Carcinoma
by: Andrew Kennedy
Published: (2016-05-01)

The next frontier in immunotherapy: potential and challenges of CAR-macrophages
by: Jing Li, et al.
Published: (2024-08-01)

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice
by: Mei-Fang Cheng, et al.
Published: (2024-06-01)

Process failure mode and effects analysis for external beam radiotherapy: Introducing a literature-based template and a novel action priority
by: Dominik Kornek, et al.
Published: (2024-08-01)

Macrophages and tumor-associated macrophages in the senescent microenvironment: From immunosuppressive TME to targeted tumor therapy
by: Ming Du, et al.
Published: (2024-06-01)

Synthesis and Biological Evaluation of <sup>99m</sup>Tc(I) Tricarbonyl Complexes Dual-Targeted at Tumoral Mitochondria
by: Diogo Figueiredo, et al.
Published: (2021-01-01)

Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
by: Asta Juzeniene, et al.
Published: (2023-01-01)

Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy
by: Min Li, et al.
Published: (2023-06-01)

Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
by: Laurel B. Darragh, et al.
Published: (2019-01-01)

Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy?
by: Ruiwen Zhao, et al.
Published: (2024-07-01)

New opportunities for nanoparticles in cancer immunotherapy
by: Wooram Park, et al.
Published: (2018-09-01)

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
by: Amit Kumar, et al.
Published: (2022-06-01)

Editorial: Role of fibroblast in cancer
by: Xuezhen Zeng, et al.
Published: (2025-02-01)

Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease
by: Stefan Forster, et al.
Published: (2022-07-01)

Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands
by: Kim E. de Roode, et al.
Published: (2024-02-01)

In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation
by: Circe D. van der Heide, et al.
Published: (2024-12-01)

Editorial: Women in radionuclide therapy: 2023
by: Egesta Lopci, et al.
Published: (2024-05-01)

Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy
by: Isabel Heidegger, et al.
Published: (2019-06-01)

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
by: G Giuffrida, et al.
Published: (2019-05-01)

Editorial: Crosstalk between cancer-associated fibroblasts and tumor cells in the tumor microenvironment: an emerging target of anti-cancer immunotherapy
by: Chunxue Zhang, et al.
Published: (2023-08-01)

Production of 161Tb Radionuclide
by: Ruyu WANG, et al.
Published: (2024-08-01)